HLB bioStep Co.,Ltd.

KOSDAQ:A278650 Stock Report

Market Cap: ₩51.4b

HLB bioStepLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for HLB bioStepLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth23.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Jan 23

Is HLB bioStepLtd (KOSDAQ:278650) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Nov 04

HLB bioStep Co.,Ltd.'s (KOSDAQ:278650) Business And Shares Still Trailing The Industry

HLB bioStep Co.,Ltd.'s ( KOSDAQ:278650 ) price-to-sales (or "P/S") ratio of 2x might make it look like a buy right now...
Analysis Article • Mar 21

Revenues Working Against HLB bioStep Co.,Ltd.'s (KOSDAQ:278650) Share Price Following 29% Dive

HLB bioStep Co.,Ltd. ( KOSDAQ:278650 ) shares have had a horrible month, losing 29% after a relatively good period...
Analysis Article • Jan 03

Unpleasant Surprises Could Be In Store For HLB bioStep Co.,Ltd.'s (KOSDAQ:278650) Shares

It's not a stretch to say that HLB bioStep Co.,Ltd.'s ( KOSDAQ:278650 ) price-to-sales (or "P/S") ratio of 3.4x right...
Analysis Article • Oct 21

Does HLB bioStepLtd (KOSDAQ:278650) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jul 17

Is HLB bioStepLtd (KOSDAQ:278650) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article • May 22

HLB bioStep Co.,Ltd. (KOSDAQ:278650) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely

The HLB bioStep Co.,Ltd. ( KOSDAQ:278650 ) share price has fared very poorly over the last month, falling by a...
Analysis Article • Mar 29

Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%

Despite an already strong run, HLB bioStep Co.,Ltd. ( KOSDAQ:278650 ) shares have been powering on, with a gain of 29...
Analysis Article • Feb 28

Here's Why HLB bioStepLtd (KOSDAQ:278650) Has A Meaningful Debt Burden

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Mar 17

With EPS Growth And More, KNOTUSLtd (KOSDAQ:278650) Is Interesting

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Feb 24

What Kind Of Investors Own Most Of KNOTUS Co.,Ltd (KOSDAQ:278650)?

If you want to know who really controls KNOTUS Co.,Ltd ( KOSDAQ:278650 ), then you'll have to look at the makeup of its...
Analysis Article • Feb 03

Is KNOTUSLtd (KOSDAQ:278650) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jan 13

Investors Who Bought KNOTUSLtd (KOSDAQ:278650) Shares A Year Ago Are Now Up 26%

The KNOTUS Co.,Ltd ( KOSDAQ:278650 ) share price has had a bad week, falling 14%. Taking a longer term view we see the...
Analysis Article • Dec 23

Should We Be Delighted With KNOTUS Co.,Ltd's (KOSDAQ:278650) ROE Of 15%?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Analysis Article • Dec 02

Is Now The Time To Put KNOTUSLtd (KOSDAQ:278650) On Your Watchlist?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as HLB bioStepLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A278650 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202673,958-19,277-4,399-2,360N/A
12/31/202574,050-18,9621,0273,086N/A
9/30/202571,466-7,618-18,296-17,600N/A
6/30/202566,029-9,164-15,037-13,979N/A
3/31/202560,180-8,066-9,231-7,912N/A
12/31/202458,169-8,564-20,597-11,670N/A
9/30/202456,755-4,939-20,924-10,099N/A
6/30/202449,166-6,147-15,906-3,229N/A
3/31/202450,588-2,806-17,992-5,887N/A
12/31/202352,814-1641,1865,192N/A
9/30/202362,832-1,3683,4567,093N/A
6/30/202374,209-8965,4049,096N/A
3/31/202382,152-1,4352,4658,333N/A
12/31/202286,277-1,0084226,481N/A
9/30/202281,3604,934-3,3419,935N/A
6/30/202274,4217,590-8,4285,751N/A
3/31/202267,6959,911-5,6088,849N/A
12/31/202164,40311,031-11,2438,463N/A
9/30/202161,9348,423-4,7319,694N/A
6/30/202158,6618,5112,28414,214N/A
3/31/202158,5288,4631,80911,805N/A
12/31/202058,5208,3026,92811,464N/A
9/30/202055,2697,3381,5633,909N/A
6/30/202054,9026,322-1703,284N/A
3/31/202049,7765,3021,1134,410N/A
12/31/201946,0404,195N/A5,182N/A
9/30/201942,8213,495N/A8,092N/A
6/30/201941,9654,248N/A7,412N/A
3/31/201940,3903,816N/A5,859N/A
12/31/201837,2373,554N/A3,450N/A
12/31/201729,3404,910N/A1,216N/A
12/31/201611,1582,435N/A3,134N/A
12/31/20156,324573N/A2,102N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A278650's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A278650's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A278650's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A278650's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A278650's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A278650's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 12:11
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HLB bioStep Co.,Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joong SoSK Securities Co., Ltd.